Abstract
Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN- is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
Keywords: Type I interferons, interferon-alpha, interferon-beta, STATs, mTOR, pegylated interferons, farnesyltransferase inhibitors, EGF-R, cytokine, antitumor activity
Protein & Peptide Letters
Title:Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Volume: 20 Issue: 4
Author(s): Michele Caraglia, Alessandra Dicitore, Monica Marra, Sara Castiglioni, Luca Persani, Pasquale Sperlongano, Pierosandro Tagliaferri, Alberto Abbruzzese and Giovanni Vitale
Affiliation:
Keywords: Type I interferons, interferon-alpha, interferon-beta, STATs, mTOR, pegylated interferons, farnesyltransferase inhibitors, EGF-R, cytokine, antitumor activity
Abstract: Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN- is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
Export Options
About this article
Cite this article as:
Caraglia Michele, Dicitore Alessandra, Marra Monica, Castiglioni Sara, Persani Luca, Sperlongano Pasquale, Tagliaferri Pierosandro, Abbruzzese Alberto and Vitale Giovanni, Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties, Protein & Peptide Letters 2013; 20 (4) . https://dx.doi.org/10.2174/0929866511320040005
DOI https://dx.doi.org/10.2174/0929866511320040005 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Unique Intracellular, Extracellular and Transmembrane Circulation of Potassium Ions in the Auditory Inner Ear as an Anticarcinogenic Principle? Part 1
Inflammation & Allergy - Drug Targets (Discontinued) <i>Ajuga</i> L.: A Systematic Review on Chemical Composition, Phytopharmacological and Biological Potential
Current Bioactive Compounds Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Oxidative Stress Protection by Novel Telomerase Activators in Mesenchymal Stem Cells Derived from Healthy and Diseased Individuals
Current Molecular Medicine Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Imaging with Raman Spectroscopy
Current Pharmaceutical Biotechnology MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Breast Cancer Image Classification: A Review
Current Medical Imaging Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Exploring Optic Nerve Axon Regeneration
Current Neuropharmacology Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science Colon Cancer Therapy: Recent Developments in Nanomedicine to Improve the Efficacy of Conventional Chemotherapeutic Drugs
Anti-Cancer Agents in Medicinal Chemistry FOXO1: A Potential Target for Human Diseases
Current Drug Targets Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
Current Molecular Medicine Polyunsaturated Fatty Acids in Pathological Retinal Angiogenesis
Current Nutrition & Food Science Polynucleotide Kinase as a Potential Target for Enhancing Cytotoxicity by Ionizing Radiation and Topoisomerase I Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Recent Patents on Anti-Cancer Drug Discovery Current Perspectives on Novel Drug Delivery Systems and Approaches for Management of Cervical Cancer: A Comprehensive Review
Current Drug Targets Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond
Current Medicinal Chemistry